drugset
drugset / Trial / NCT05366751

A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

NCT05366751 ↗

Phase 2/3 Terminated 97 enrolled Sage Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the long-term safety and tolerability of SAGE-324 in participants with essential tremor (ET).

Timeline

Start
2022-06-03
Primary completion
2024-09-10
Completion
2024-09-10

Outcome

Outcome not reported

Stopped: “Internal company decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject SAGE-324 Unknown 60 mg Oral

Indications

essential tremor